Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (260)	6/18/2002 11:46:34 AM
From: keokalani'nui	Read Replies (1) of 625

From "3-5%", to "around 5%", to "5%". Who is to say Reuters is right. By Richard Woodman STOCKHOLM, June 14 (Reuters) - Abbott Laboratories Inc said on Friday latest trial results confirmed the safety and efficacy of a potential blockbuster rheumatoid arthritis drug. Abbott filed for regulatory approval of D2E7 in April. It is one of a new class of injectable antibody drugs designed to block a protein called tumor necrosis factor, or TNF, which is involved in inflammation. Abbott (NYSE:ABT - News) expects peak annual sales in excess of $1 billion within four to five years of launch, helped by the product's more convenient dosing regime compared with its rivals. Britain's Cambridge Antibody Technology Plc, which helped develop the drug, will receive a 5 percent royalty on sales of D2E7. It is the first monoclonal antibody made entirely from human protein, minimizing the risk of side effects. Current drugs are either man-made or made with a portion of mouse protein.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next